Harm & urgent help
Harm: what the evidence can and cannot tell us
The September 2026 record does not tell us enough about what harm BPC-157 might cause. Keep that gap in view when weighing a claim that it has no problems.
Know when help cannot wait.
Seek emergency care for severe symptoms of an allergic reaction, such as trouble breathing or a swollen tongue. MedlinePlus emergency guidance
Use those signs to seek help; they cannot tell you the cause.
Do not read small studies as proof of safety.
The US drug-review agency is FDA, which stands for Food and Drug Administration.
FDA found that the BPC-157 studies were brief, small and often unclear about how they tracked harm.
No serious harm appeared in those study reports, but FDA judged the safety information inadequate. FDA harm review
Reports cannot tell us the cause or how often harm occurs.
FDA’s review found reports of redness and swelling after injection, trouble breathing, and darkened skin and gums.
It could not establish BPC-157 as the cause; the reports also cannot tell us how often problems occur. FDA report review
Ask about the body’s reaction to the substance.
An immune response is the body treating a substance as an invader.
FDA raised concerns about an immune response to BPC-157 given by injection or through the nose.
The risk could be greater if BPC-157 sticks together in clumps within the medicine, or if unwanted material is mixed into it.
No study had directly checked for this immune reaction to BPC-157; FDA was warning about a possible problem, rather than reporting how often it happened. FDA immune concerns
Know what an absent label means.
BPC-157 had no FDA-reviewed label with pregnancy details or information on how it might affect other medicines (September 2026). FDA information gap
FDA found no human pregnancy study of it.
Raise pregnancy, plans for pregnancy and all medicines in the assessment. Do not fill missing information with a claim from an advert.